Annals of internal medicine
-
Randomized Controlled Trial Multicenter Study
Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.
Inhaled corticosteroids (ICS) and long-acting β(2)-agonists (LABAs) are recommended in patients with asthma that is not well-controlled; however, many patients continue to have inadequately controlled asthma despite this therapy. ⋯ Genentech and Novartis Pharmaceuticals.